CARM

CARM

USD

Carisma Therapeutics Inc. Common Stock

$0.403-0.004 (-1.080%)

Reaalajas hind

Healthcare
Biotehnoloogia
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$0.407

Kõrge

$0.427

Madal

$0.400

Maht

0.85M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

16.8M

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

14.47M

Börs

NCM

Valuuta

USD

52 nädala vahemik

Madal $0.142Praegune $0.403Kõrge $1.38

Seotud uudised

PR Newswire

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: CARM, GNTY, TSBX, and SAGE

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...

Vaata rohkem
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: CARM, GNTY, TSBX, and SAGE
PR Newswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, GNTY on Behalf of Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

Vaata rohkem
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, GNTY on Behalf of Shareholders
PR Newswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE and CARM on Behalf of Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

Vaata rohkem
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE and CARM on Behalf of Shareholders
GlobeNewswire

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform, focused on

Vaata rohkem
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.